The DOI matches its Crossref record; 1,861 of the 1,959 references it cites were found in a registry or an index; 7 of the 11 sources its claims cite were checked for support.
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.
Open accessAbstract
Objective The objective of this clinical practice guideline is to provide updated and new evidence-based recommendations for the comprehensive care of persons with diabetes mellitus to clinicians, diabetes-care teams, other health care professionals and stakeholders, and individuals with diabetes and their caregivers. Methods The American Association of Clinical Endocrinology selected a task force of medical experts and staff who updated and assessed clinical questions and recommendations from the prior 2015 version of this guideline and conducted literature searches for relevant scientific papers published from January 1, 2015, through May 15, 2022. Selected studies from results of literature searches composed the evidence base to update 2015 recommendations as well as to develop new recommendations based on review of clinical evidence, current practice, expertise, and consensus, according to established American Association of Clinical Endocrinology protocol for guideline development. Results This guideline includes 170 updated and new evidence-based clinical practice recommendations for the comprehensive care of persons with diabetes. Recommendations are divided into four sections: (1) screening, diagnosis, glycemic targets, and glycemic monitoring; (2) comorbidities and complications, including obesity and management with lifestyle, nutrition, and bariatric surgery, hypertension, dyslipidemia, retinopathy, neuropathy, diabetic kidney disease, and cardiovascular disease; (3) management of prediabetes, type 2 diabetes with antihyperglycemic pharmacotherapy and glycemic targets, type 1 diabetes with insulin therapy, hypoglycemia, hospitalized persons, and women with diabetes in pregnancy; (4) education and new topics regarding diabetes and infertility, nutritional supplements, secondary diabetes, social determinants of health, and virtual care, as well as updated recommendations on cancer risk, nonpharmacologic components of pediatric care plans, depression, education and team approach, occupational risk, role of sleep medicine, and vaccinations in persons with diabetes. Conclusions This updated clinical practice guideline provides evidence-based recommendations to assist with person-centered, team-based clinical decision-making to improve the care of persons with diabetes mellitus.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
20 Own method · 2 Partly supported · 1 Couldn’t confirm · 1 No basis given · accuracy not yet measured
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“A glucose level ≥200 mg/dL in the presence of hyperglycemia symptoms such as polyuria and polydipsia confirm the diagnosis of DM.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the sources say
- Could not verifycites [6] sourceExperimental — accuracy not yet measured
The Diagnostic testing passage (page unavailable) discusses fasting glucose, HbA1c, C-peptide, and antibody tests for evaluating MODY. Neither it nor the other retrieved passages gives a ≥200 mg/dL glucose threshold with hyperglycemia symptoms for diagnosing diabetes; searches for that threshold and symptom-based criterion found no supporting passage in our copy. (LLM, conf=0.73)
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The concordance between FPG, 2-hour PG, and A1C is not perfect; thus, the diagnosis of DM requires 2 different (fasting glucose and A1C) abnormal test results, either from the same sample or 2 abnormal results on samples drawn on different days.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the sources say
- Partly supportedcites [3] sourceExperimental — accuracy not yet measured
The paper’s introductory passage says diabetes diagnosis requires confirmation of an elevated glucose or HbA1c result and that two different tests above diagnostic thresholds can provide confirmation. It also says repeating the same test on a later sample is preferred, so two different tests are not required. The Discussion says guidelines were unclear about using two tests from one sample; our copy does not address the quoted exception for symptoms with glucose of at least 200 mg/dL or concordance involving 2-hour PG. (LLM, conf=0.87)
- Partly supportedcites [4] sourceExperimental — accuracy not yet measured
The paper’s opening section says that FPG or 2-hour glucose meets the usual diagnostic criteria when abnormal on more than one occasion, and that classic symptoms with a single random plasma glucose of at least 200 mg/dL are diagnostic. It does not say that confirmation requires two different tests (FPG and A1C), or that two abnormal results from the same sample suffice. Its discussion of test variability supports imperfect reproducibility, but not that specific confirmation rule. (LLM, conf=0.88)
- Partly supportedcites [5] sourceExperimental — accuracy not yet measured
The Discussion reports imperfect agreement among HbA1c, fasting plasma glucose, and 2-hour plasma glucose, and says diabetes diagnosis requires repeated measurement rather than a single test. It does not specify that the two abnormal results must be from different tests, describe the same-sample or different-day options, or state an exception for hyperglycemic symptoms with glucose of at least 200 mg/dL. (LLM, conf=0.88)
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Universal screening is recommended, as selective screening (only in women with risk factors) would miss a significant number of women with GDM and universal screening has been shown to be cost-effective compared with selective screening.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the sources say
- Not matchedcites [9]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [50] sourceExperimental — accuracy not yet measured
The Conclusions recommend GDM screening at 24–28 weeks using a 75-g OGTT. The paper does not compare universal screening with risk-factor-based selective screening or report that universal screening is cost-effective; searches for selective screening and cost-effectiveness found no such comparison. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [51] source
- Not checked — no full text of the sourcecites [52] source
- Not checked — no full text of the sourcecites [53] source
- Partly supportedcites [54] sourceExperimental — accuracy not yet measured
Section 5.2 recommends universal testing because risk-factor-based selective testing has poor sensitivity for detecting GDM. But section 5.4 says there is a lack of good evidence for the cost-effectiveness of universal testing in both high- and low-resource countries; it does not establish that universal screening is cost-effective compared with selective screening. (LLM, conf=0.90)
- Could not verifycites [55] sourceExperimental — accuracy not yet measured
The Conclusions discuss childhood glucose outcomes after maternal GDM, not whether universal screening is recommended. Searches of our copy for selective screening, missed cases, and cost-effectiveness found no passage addressing those claims. (LLM, conf=0.76)
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Real-time CGM (rtCGM) or isCGM is recommended for all persons with T1D, regardless of insulin delivery system, to improve A1C levels and to reduce the risk for hypoglycemia and DKA.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 3: When and how should glucose monitoring be used?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“DM is diagnosed by using any of 3 established criteria for elevated blood glucose (BG) concentrations (Table 4). FPG ≥126 mg/dL, 2-hour PG ≥ 200 mg/dL during 75-g OGTT, and A1C ≥ 6.5% are equally appropriate for diagnostic screening (Table 4).”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For most hospitalized persons with hyperglycemia in both the intensive care unit (ICU) and non-ICU settings, a glucose range of 140 to 180 mg/dL is recommended, provided this target can be safely achieved (Table 6).”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 2. What are the glycemic treatment goals for persons with DM?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Diabetic peripheral neuropathy (DPN) is a clinical diagnosis. A comprehensive differential diagnosis should be considered to rule out nondiabetic neuropathies.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Question 8: How should neuropathy be diagnosed and managed in persons with DM?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All persons who use insulin should use CGM or perform BG monitoring (BGM) a minimum of twice daily and ideally before any insulin injection.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 3: When and how should glucose monitoring be used?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A1C should be measured at least semiannually in all persons with DM and at least quarterly in persons not at their glycemic target.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Question 3: When and how should glucose monitoring be used?
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Screening for DPN should be done at diagnosis of T2D, within 5 years of the diagnosis of T1D, and subsequently annually or whenever symptoms occur, by performing a clinical history and physical exam.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Question 8: How should neuropathy be diagnosed and managed in persons with DM?
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Continuous access to CGM for daily use is suggested for people living with T2DM at higher risk of hypoglycaemia, similar to the current CGM clinical practice guideline recommendations from Diabetes Canada 56 and the American Association of Clinical Endocrinologists. 57”
From Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials (2025) · cites this paper as [57]
Experimental — accuracy not yet measuredIn the citing paper
“Approximately 2–5 times more patients discontinued orforglipron versus placebo due to adverse events, comparable to other GLP‐1 receptor agonists where 5%–15% discontinue in clinical trials [48].”
From Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis (2025) · cites this paper as [48]
In the citing paper
“Current guideline recommendations by the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), American College of Sports Medicine (ACSM), American Association of Clinical Endocrinology (AACE), and the American Heart Association (AHA) advocate regular resistance and aerobic exercise, as well as physical activity such as increasing daily steps to avoid sed”
From The Impact of Physical Activity in Patients With Type 2 Diabetes (2025) · cites this paper as [23]
In the citing paper
“AACE and the ADA recommend avoiding no more than 2 to 3 days between exercise routines to maintain improvement in insulin sensitivity.”
From The Impact of Physical Activity in Patients With Type 2 Diabetes (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Question 6: How should DKD or CKD in DM be managed?
“An SGLT2i with proven benefit is recommended as foundational therapy for persons with T2D and CKD with eGFR ≥20 mL/min/1.73 m2 to reduce progression of CKD and risk of CVD.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Evidence Base 6: How should DKD or CKD in DM be managed?
“An SGLT2i with proven kidney protection is recommended for people with T2D who have an eGFR >25 mL/min/1.73 m2 irrespective of albuminuria to reduce risks of DKD or CKD in DM and CVD.425,443–469 In those with HF, one agent in the class, empagliflozin, can be used with an eGFR as low as 20 mL/min/1.73 m2.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Section 1: Screening, Diagnosis, Glycemic Targets, and Glycemic Monitoring
“The one-step approach uses a 2-hour 75-g oral glucose tolerance test (OGTT) after ≥8 hours of fasting with diagnostic cutoffs of one or more FPG ≥92 mg/dL, 1-hour PG ≥180 mg/dL, or 2-hour PG ≥153 mg/dL.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 3: Management of Prediabetes, T2D, and T1D With Selection of Glycemic Targets, Lifestyle Interventions, and Antihyperglycemic Pharmacotherapy (Insulin Therapy for all With T1D and Select Individuals With T2D); Prevention, Identification, and Treatment of Hypoglycemia; Treatment of Hospitalized Persons With DM or Those With Hyperglycemia Without Diagnosis of DM; and Women With GDM > Evidence Base 16: How should DM in pregnancy be managed?
“Glucose criteria diagnostic for GDM are an FPG >92 mg/dL, 1-hour postglucose challenge value ≥180 mg/dL, or 2-hour value ≥153 mg/dL.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Evidence Base 10: How should obesity be managed in persons with DM?
“A phase 2 study in persons with biopsy-proven NASH using a daily injection equivalent to semaglutide 2.4 g/week demonstrated 13% weight loss”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Section 2: Comorbidities and Complications > Evidence Base 10: How should obesity be managed in persons with DM?
“Subcutaneous semaglutide at the higher dose of 2.4 mg/week has been approved for chronic weight management”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Section 1: Screening, Diagnosis, Glycemic Targets, and Glycemic Monitoring
“Diagnosis of DM requires 2 abnormal test results, either from the same sample or 2 abnormal results on samples drawn on different days.”
§ American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Pland—2022 Update > Recommendations and Evidence Bases > Evidence Base 1: How is the diagnosis of DM made and what is the current screening protocol for prediabetes and DM?
“the diagnosis of DM requires 2 different (fasting glucose and A1C) abnormal test results, either from the same sample or 2 abnormal results on samples drawn on different days.”
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Adler, 2021, Reprint of: Classification of diabetes mellitus, Diabetes Res Clin Pract, 10.1016/j.diabres.2021.108972”
Cited work 10.1016/j.diabres.2021.108972 · retracted 2021-07-31 · notice 10.1016/j.diabres.2021.108972 · this paper published 2022-10
Citations
Cites
1 retracted
Items 1,401–1,600 of 1,862
Zhao, L., Tian, X., Duan, X., Ye, Y., Sun, M., & Huang, J. (2017) · Oncotarget · doi:10.18632/oncotarget.16722 · Cited by 46
Kramer, M. K., Vanderwood, K. K., Arena, V. C., Miller, R. G., Meehan, R., Eaglehouse, Y. L., Schafer, G., Venditti, E. M., & Kriska, A. M. (2018) · The Diabetes Educator · doi:10.1177/0145721718759982 · Cited by 46
Carter, B. L., Levy, B., Gryzlak, B., Xu, Y., Chrischilles, E., Dawson, J., Vander Weg, M., Christensen, A., James, P., & Polgreen, L. (2018) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.117.004188 · Cited by 46
Rajan, S., Campagnolo, M., Callaghan, B. C., & Gibbons, C. H. (2018) · Clinical Autonomic Research · doi:10.1007/s10286-018-0540-0 · Cited by 46
Gomez‐Marin, B., Gómez-Delgado, F., López-Moreno, J., Alcala-Diaz, J. F., Jiménez-Lucena, R., Torres-Peña, J. D., García‐Ríos, A., Ortiz-Morales, A. M., Yubero‐Serrano, E. M., Malagón, M. M., et al. (2018) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy144 · Cited by 46
Mandel, S. R., Langan, S. J., Mathioudakis, N. N., Sidhaye, A. R., Bashura, H., Bie, J. Y., Mackay, P., Tucker, C., Demidowich, A. P., Simonds, W. F., et al. (2019) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2019.1593782 · Cited by 46
Life style intervention improves retinopathy status-the Finnish Diabetes Prevention Study
Aro, A., Kauppinen, A., Kivinen, N., Selander, T., Kinnunen, K., Tuomilehto, J., Keinänen-Kiukaanniemi, S., Lindström, J., Uusitupa, M., & Kaarniranta, K. (2019) · Nutrients · doi:10.3390/nu11071691 · Cited by 46
Novel preparations of glucagon for the prevention and treatment of hypoglycemia
Hawkes, C. P., De Leon, D. D., & Rickels, M. R. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1216-4 · Cited by 46
Kawai, Y., Uneda, K., Yamada, T., Kinguchi, S., Kobayashi, K., Azushima, K., Kanaoka, T., Toya, Y., Wakui, H., & Tamura, K. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109146 · Cited by 46
Admission hypoglycemia and increased mortality in patients hospitalized with pneumonia
Gamble, J.-M., Eurich, D. T., Marrie, T. J., & Majumdar, S. R. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.11.021 · Cited by 45
Cho, J. H., Kim, H.-S., Yoo, S. H., Jung, C. H., Lee, W. J., Park, C. Y., Yang, H. K., Park, J. Y., Park, S. W., & Yoon, K. H. (2017) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x16657500 · Cited by 45
Hu, Y.-M., Zhou, F., Yuan, Y., & Xu, Y.-C. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2016.11.036 · Cited by 45
Replacement Effects of Sedentary Time on Metabolic Outcomes: The Maastricht Study
VAN DER BERG, J. D., VAN DER VELDE, J. H. P. M., DE WAARD, E. A. C., BOSMA, H., SAVELBERG, H. H. C. M., SCHAPER, N. C., VAN DEN BERGH, J. P. W., GEUSENS, P. P. M. M., SCHRAM, M. T., SEP, S. J. S., et al. (2017) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001248 · Cited by 45
Health effectiveness of community health workers as a diabetes self-management intervention
Aponte, J., Jackson, T., Wyka, K., & Ikechi, C. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117696229 · Cited by 45
Perez-Lopez, F. R., Pasupuleti, V., Gianuzzi, X., Palma-Ardiles, G., Hernandez-Fernandez, W., & Hernandez, A. V. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.04.001 · Cited by 45
Boeri, L., Capogrosso, P., Ventimiglia, E., Pederzoli, F., Frego, N., Cazzaniga, W., Chierigo, F., Alfano, M., Piemonti, L., Viganò, P., et al. (2019) · BJU International · doi:10.1111/bju.14558 · Cited by 45
Wang, J., Chen, Y., Xu, W., Lu, N., Cao, J., & Yu, S. (2019) · PLOS ONE · doi:10.1371/journal.pone.0215362 · Cited by 45
Akbari, M., Tamtaji, O. R., Lankarani, K. B., Tabrizi, R., Dadgostar, E., Kolahdooz, F., Jamilian, M., Mirzaei, H., & Asemi, Z. (2019) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-019-00324-6 · Cited by 45
Leiter, L. A., Bain, S. C., Bhatt, D. L., Buse, J. B., Mazer, C. D., Pratley, R. E., Rasmussen, S., Ripa, M. S., Vrazic, H., & Verma, S. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14079 · Cited by 45
Pasquel, F. J., Lansang, M. C., Khowaja, A., Urrutia, M. A., Cardona, S., Albury, B., Galindo, R. J., Fayfman, M., Davis, G., Migdal, A., et al. (2020) · Diabetes Care · doi:10.2337/dc19-1940 · Cited by 45
Self-citationTetanus surveillance --- United States, 2001-2008.
(2011) · PubMed · Cited by 45
Guo, F., & Garvey, W. T. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2691 · Cited by 44
Self-citationKu, G. M., & Kegels, G. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005317 · Cited by 44
Glycemic Characteristics and Neonatal Outcomes of Women Treated for Mild Gestational Diabetes
Durnwald, C. P., Mele, L., Spong, C. Y., Ramin, S. M., Varner, M. W., Rouse, D. J., SCISCIONE, A. C., Catalano, P. M., Saade, G. R., Sorokin, Y., et al. (2011) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31820fc6cf · Cited by 44
Vora, J., Cohen, N., Evans, M., Hockey, A., Speight, J., & Whately‐Smith, C. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12528 · Cited by 44
Glucose Variability and Mortality in Patients Hospitalized With Acute Myocardial Infarction
Lipska, K. J., Venkitachalam, L., GOSCH, K. L., Kovatchev, B. P., den Berghe, G. V., Meyfroidt, G., Jones, P. G., Inzucchi, S. E., Spertus, J. A., DeVries, J. H., et al. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.963298 · Cited by 44
Self-citationEconomic evaluation of chronic disease self-management for people with diabetes: A systematic review
Teljeur, C., Moran, P. S., Walshe, S., Smith, S. M., Cianci, F., Murphy, L., Harrington, P., & Ryan, M. (2017) · Diabetic Medicine · doi:10.1111/dme.13281 · Cited by 44
Lo, C., Jun, M., Badve, S. V., Pilmore, H., White, S. L., Hawley, C. M., Cass, A., Perkovic, V., & Zoungas, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009966.pub2 · Cited by 44
Brouwer, T. F., Vehmeijer, J. T., Kalkman, D. N., Berger, W. R., van den Born, B.-J. H., Peters, R. J., & Knops, R. E. (2018) · Diabetes Care · doi:10.2337/dc17-1722 · Cited by 44
Shi, J., Liu, B., Wang, H., Zhang, T., & Yang, L. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2018-000060 · Cited by 44
Concentrated insulins: Clinical update of therapeutic options
Umpierrez, G. E., Holt, E. H., Einhorn, D., & McGill, J. B. (2020) · Endocrine Practice · doi:10.4158/ep-2019-0607 · Cited by 44
Self-citationWeissberg-Benchell, J., Shapiro, J. B., Bryant, F. B., & Hood, K. K. (2020) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000608 · Cited by 44
Fornes, R., Simin, J., Nguyen, M. H., Cruz, G., Crisosto, N., van der Schaaf, M., Engstrand, L., & Brusselaers, N. (2022) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-022-00905-6 · Cited by 44
Rosenstock, J., Franco, D., Korpachev, V., Shumel, B., Ma, Y., Baughman, R., Amin, N., McGill, J. B., & for the Affinity 2 Study Group (2015) · Diabetes Care · doi:10.2337/dc15-0629 · Cited by 43
Self-citationJohannsen, N. M., Swift, D. L., Lavie, C. J., Earnest, C. P., Blair, S. N., & Church, T. S. (2013) · Diabetes Care · doi:10.2337/dc12-2194 · Cited by 43
Adiposity Predicts Cognitive Decline in Older Persons with Diabetes: A 2-Year Follow-Up
Abbatecola, A. M., Lattanzio, F., Spazzafumo, L., Molinari, A. M., Cioffi, M., Canonico, R., Cioccio, L. D., & Paolisso, G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010333 · Cited by 43
Mathiesen, E. R., Damm, P., Jovanovic, L., McCance, D. R., Thyregod, C., Jensen, A. B., & Hod, M. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1213 · Cited by 43
Schoenaker, D. A. J. M., Simon, D., Chaturvedi, N., Fuller, J. H., Soedamah-Muthu, S. S., & the EURODIAB Prospective Complications Study Group (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2824 · Cited by 43
Ard, J., Cannon, A., Lewis, C. E., Lofton, H., Vang Skjøth, T., Stevenin, B., & Pi‐Sunyer, X. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12632 · Cited by 43
Inpatient HbA1c testing: a prospective observational study
Nanayakkara, N., Nguyen, H., Churilov, L., Kong, A., Pang, N., Hart, G. K., Owen-Jones, E., White, J., Ross, J., Stevenson, V., et al. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000113 · Cited by 43
the FinnDiane Study Group, Tikkanen-Dolenc, H., Wadén, J., Forsblom, C., Harjutsalo, V., Thorn, L. M., Saraheimo, M., Elonen, N., Hietala, K., Summanen, P., et al. (2020) · Acta Diabetologica · doi:10.1007/s00592-019-01454-y · Cited by 43
Shi, Y.-Q., Zhou, X.-C., Du, P., Yin, M.-Y., Xu, L., Chen, W.-J., & Xu, C.-F. (2020) · Medicine · doi:10.1097/md.0000000000021687 · Cited by 43
Sadosky, A., Hopper, J., & Parsons, B. (2014) · The Patient - Patient-Centered Outcomes Research · doi:10.1007/s40271-013-0038-8 · Cited by 42
Different insulin types and regimens for pregnant women with pre-existing diabetes
O’Neill, S. M., Kenny, L. C., Khashan, A. S., West, H., Smyth, R. M., & Kearney, P. M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011880.pub2 · Cited by 42
Haymond, M. W., DuBose, S. N., Rickels, M. R., Wolpert, H., Shah, V. N., Sherr, J. L., Weinstock, R. S., Agarwal, S., Verdejo, A. S., Cummins, M. J., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00591 · Cited by 42
Buckley, L. F., Dixon, D. L., Wohlford, G. F., Wijesinghe, D. S., Baker, W. L., & Van Tassell, B. W. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13248 · Cited by 42
Lucaroni, F., Cicciarella Modica, D., Macino, M., Palombi, L., Abbondanzieri, A., Agosti, G., Biondi, G., Morciano, L., & Vinci, A. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030234 · Cited by 42
Dwyer, A. A., Chavan, N. R., Lewkowitz-Shpuntoff, H., Plummer, L., Hayes, F. J., Seminara, S. B., Crowley, W. F., Pitteloud, N., & Balasubramanian, R. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02697 · Cited by 41
Accuracy of Blood Glucose Measurement and Blood Glucose Targets
Eerdekens, G.-J., Rex, S., & Mesotten, D. (2020) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820905581 · Cited by 41
Lau, D., Eurich, D. T., Majumdar, S. R., Katz, A., & Johnson, J. A. (2014) · Diabetologia · doi:10.1007/s00125-013-3158-8 · Cited by 41
Buse, J. B., Kudva, Y. C., Battelino, T., Davis, S. N., Shin, J., & Welsh, J. B. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0294 · Cited by 41
Molecular genetic testing of patients with monogenic diabetes and hyperinsulinism
Bennett, J. T., Vasta, V., Zhang, M., Narayanan, J., Gerrits, P., & Hahn, S. H. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2014.12.304 · Cited by 41
Cheungpasitporn, W., Thongprayoon, C., Vijayvargiya, P., Anthanont, P., & Erickson, S. B. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.03.001 · Cited by 41
Miguel-Berges, M. L., Reilly, J. J., Moreno Aznar, L. A., & Jiménez-Pavón, D. (2018) · Clinical Journal of Sport Medicine · doi:10.1097/jsm.0000000000000419 · Cited by 41
Effects of before-school physical activity on obesity prevention and wellness
Whooten, R. C., Perkins, M. E., Gerber, M. W., & Taveras, E. M. (2018) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2018.01.017 · Cited by 41
Laranjeira, F. O., de Andrade, K. R. C., Figueiredo, A. C. M. G., Silva, E. N., & Pereira, M. G. (2018) · PLOS ONE · doi:10.1371/journal.pone.0194801 · Cited by 41
Selenium supplementation and insulin resistance in a randomized, clinical trial
Jacobs, E. T., Lance, P., Mandarino, L. J., Ellis, N. A., Chow, H.-H. S., Foote, J., Martinez, J. A., Hsu, C.-H. P., Batai, K., Saboda, K., et al. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000613 · Cited by 41
Fushimi, N., Shibuya, T., Yoshida, Y., Ito, S., Hachiya, H., & Mori, A. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13093 · Cited by 41
Ruof, J., Golay, A., Berne, C., Collin, C., Lentz, J., & Maetzel, A. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802925 · Cited by 40
DPP-4 Inhibitor–Related Pancreatitis: Rare but Real!
DeVries, J. H., & Rosenstock, J. (2017) · Diabetes Care · doi:10.2337/dci16-0035 · Cited by 40
Davis, S. N., Horton, E. S., Battelino, T., Rubin, R. R., Schulman, K. A., & Tamborlane, W. V. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0145 · Cited by 40
Self-citationHo, C.-H., Yu, H.-J., Wang, C.-Y., Jaw, F.-S., Hsieh, J.-T., Liao, W.-C., Pu, Y.-S., & Liu, S.-P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074173 · Cited by 40
Cheungpasitporn, W., Thongprayoon, C., Harindhanavudhi, T., Edmonds, P. J., & Erickson, S. B. (2016) · Endocrine Research · doi:10.3109/07435800.2015.1094088 · Cited by 40
Xue, K., Li, F.-F., Chen, Y.-W., Zhou, Y.-H., & He, J. (2017) · European Journal of Cancer Prevention · doi:10.1097/cej.0000000000000231 · Cited by 40
Cardona, S., Gomez, P., Vellanki, P., Anzola, I., Ramos, C., Urrutia, M. A., HAW, J. S., Fayfman, M., Wang, H., Galindo, R. J., et al. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000607 · Cited by 40
Self-citationJanssen, J. M., Heyward, W. L., Martin, J. T., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2014.12.060 · Cited by 39
Pontiroli, A. E. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814557518 · Cited by 39
Hypoglycemia: Minimizing its impact in type 2 diabetes
Moghissi, E., Ismail-Beigi, F., & Devine, R. C. (2013) · Endocrine Practice · doi:10.4158/ep13005.ra · Cited by 39
Tomizawa, N., Nojo, T., Inoh, S., & Nakamura, S. (2015) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-014-0542-5 · Cited by 39
Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus
Lee, N. J., Norris, S. L., & Thakurta, S. (2010) · The Annals of Family Medicine · doi:10.1370/afm.1174 · Cited by 39
Ranjan, A., Schmidt, S., Madsbad, S., Holst, J. J., & Nørgaard, K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12627 · Cited by 39
Aloi, J., Bode, B. W., Ullal, J., Chidester, P., McFarland, R. S., Bedingfield, A. E., Mabrey, M., Booth, R., Mumpower, A., & Wallia, A. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816664746 · Cited by 39
Hu, Y., Zhou, F., Yuan, Y., & Xu, Y. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.03.003 · Cited by 39
Lipš, M., Mráz, M., Kloučková, J., Kopecký, P., Dobiáš, M., Křížová, J., Lindner, J., Diamant, M., & Haluzík, M. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13029 · Cited by 39
Diabetes and blood glucose disorders under anti-PD1
Magis, Q., Gaudy-Marqueste, C., Basire, A., Loundou, A., Malissen, N., Troin, L., Monestier, S., Mallet, S., Hesse, S., Richard, M.-A., et al. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000218 · Cited by 39
Shah, B., Walji, S., Kiss, A., James, J., & Lowe, J. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.08.061 · Cited by 39
Blair, J., McKay, A., Ridyard, C. H., Thornborough, K., Bedson, E., Peak, M., Didi, M., Annan, F., Gregory, J. W., Hughes, D. A., et al. (2018) · Health Technology Assessment · doi:10.3310/hta22420 · Cited by 39
Saglimbene, V., Palmer, S. C., Ruospo, M., Natale, P., Maione, A., Nicolucci, A., Vecchio, M., Tognoni, G., Craig, J. C., Pellegrini, F., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018040443 · Cited by 39
Bjerg, L., Hulman, A., Carstensen, B., Charles, M., Witte, D. R., & Jørgensen, M. E. (2019) · Diabetologia · doi:10.1007/s00125-019-4812-6 · Cited by 39
Galindo, R. J., Pasquel, F. J., Fayfman, M., TSEGKA, K. G., Dhruv, N., Cardona, S., Wang, H., Vellanki, P., & Umpierrez, G. E. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000763 · Cited by 39
Self-citationFerretti, F., Cannatelli, R., Benucci, M., Carmagnola, S., Clementi, E., Danelli, P., Dilillo, D., Fiorina, P., Galli, M., Gallieni, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656362 · Cited by 39
Adding Liraglutide to Oral Antidiabetic Drug Monotherapy: Efficacy and Weight Benefits
Nauck, M. A., & Marre, M. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.1997 · Cited by 38
Kim, Y., Keogh, J. B., & Clifton, P. M. (2016) · Nutrients · doi:10.3390/nu8110687 · Cited by 38
Martono, D. P., Lub, R., Heerspink, H. J. L., Hak, E., Wilffert, B., & Denig, P. (2015) · Diabetic Medicine · doi:10.1111/dme.12688 · Cited by 38
Hermayer, K. L., Neal, D. E., Hushion, T. V., Irving, M. G., Arnold, P. C., Kozlowski, L., Stroud, M. R., Kerr, F. B., & Kratz, J. M. (2007) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2007.0225 · Cited by 38
Impaired glucose homeostasis in renal transplant recipients receiving basiliximab
Aasebo, W., Midtvedt, K., Valderhaug, T. G., Leivestad, T., Hartmann, A., Reisaeter, A. V., Jenssen, T., & Holdaas, H. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp617 · Cited by 38
Barr, C. C. (2001) · Survey of Ophthalmology · doi:10.1016/s0039-6257(01)00187-4 · Cited by 38
Schnell, O., Weng, J., Sheu, W. H., Watada, H., Kalra, S., Soegondo, S., Yamamoto, N., Rathod, R., Zhang, C., & Grzeszczak, W. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.01.023 · Cited by 38
Gilardini, L., Redaelli, G., Croci, M., Conti, A., Pasqualinotto, L., & Invitti, C. (2016) · Obesity Facts · doi:10.1159/000445504 · Cited by 38
Kumar, A., Franek, E., Wise, J., Niemeyer, M., Mersebach, H., & Simó, R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0163350 · Cited by 38
The impact of metformin use on survival in kidney cancer patients with diabetes: A meta-analysis
Li, Y., Hu, L., Xia, Q., Yuan, Y., & Mi, Y. (2017) · International Urology and Nephrology · doi:10.1007/s11255-017-1548-4 · Cited by 38
Besch, G., Perrotti, A., Mauny, F., Puyraveau, M., Baltres, M., Flicoteaux, G., Salomon du Mont, L., Barrucand, B., Samain, E., Chocron, S., et al. (2017) · Anesthesiology · doi:10.1097/aln.0000000000001838 · Cited by 38
Pablos, A., Nebot, V., Vañó-Vicent, V., Ceca, D., & Elvira, L. (2018) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2017-0348 · Cited by 38
Tsujimoto, T., & Kajio, H. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11408 · Cited by 38
de Carvalho, G. B., Dias-Vasconcelos, N. L., Santos, R. K. F., Brandão-Lima, P. N., da Silva, D. G., & Pires, L. V. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2019.1624498 · Cited by 38
Mobile application interventions and weight loss in type 2 diabetes: A meta-analysis
Cai, X., Qiu, S., Luo, D., Wang, L., Lu, Y., & Li, M. (2020) · Obesity · doi:10.1002/oby.22715 · Cited by 38
Fang, Z., Liu, M., Tao, J., Li, C., Zou, F., & Zhang, W. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01674-6 · Cited by 38
Huffman, C., Stacey, B. R., Tuchman, M., Burbridge, C., Li, C., Parsons, B., Pauer, L., Scavone, J. M., Behar, R., & Yurkewicz, L. (2015) · The Clinical Journal of Pain · doi:10.1097/ajp.0000000000000198 · Cited by 37
Course of HbA1c in non-diabetic pregnancy related to birth weight.
Versantvoort, A. R. E., van Roosmalen, J., & Radder, J. K. (2013) · PubMed · Cited by 37
(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus
Hemmingsen, B., Metzendorf, M.-I., & Richter, B. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013498.pub2 · Cited by 37
Economic burden of hypoglycemia in patients with type 2 diabetes
Liu, S., Zhao, Y., Hempe, J. M., Fonseca, V., & Shi, L. (2012) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.11.87 · Cited by 37
Saur, N. M., Kongable, G. L., Holewinski, S., O’Brien, K., & Nasraway, S. A. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.07.003 · Cited by 37
Chen, Y., Du, L., Li, L., Ma, J., Geng, X., Yao, X., Liu, G., & Sun, X. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12435 · Cited by 37
Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes
Ku, E., McCulloch, C. E., Mauer, M. S., Gitelman, S. E., Grimes, B. A., & Hsu, C. (2016) · Diabetes Care · doi:10.2337/dc16-0857 · Cited by 37
Guo, F., & Garvey, W. T. (2017) · Diabetes Care · doi:10.2337/dc17-0088 · Cited by 37
Self-citationWang, X., Juan, Q.-F., He, Y.-W., Zhuang, L., Fang, Y.-Y., & Wang, Y.-H. (2017) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2016-0230 · Cited by 37
Rodbard, H. W., Buse, J. B., Woo, V. C., Vilsbøll, T., Langbakke, I. H., Kvist, K., & Gough, S. C. L. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12574 · Cited by 36
Transitioning safely from intravenous to subcutaneous insulin
Kreider, K. E., & Lien, L. F. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0595-4 · Cited by 36
Vellanki, P., Bean, R., Oyedokun, F. A., Pasquel, F. J., Smiley, D., Farrokhi, F., Newton, C., Peng, L., & Umpierrez, G. E. (2015) · Diabetes Care · doi:10.2337/dc14-1796 · Cited by 36
Self-citationBattista, M.-C., Labonté, M., Ménard, J., Jean-Denis, F., Houde, G., Ardilouze, J.-L., & Perron, P. (2012) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h2012-025 · Cited by 36
De Ridder, J., Julián-Almárcegui, C., Mullee, A., Rinaldi, S., Van Herck, K., Vicente-Rodríguez, G., & Huybrechts, I. (2016) · Cancer Causes & Control · doi:10.1007/s10552-015-0709-y · Cited by 36
Maréchal, C., Lal, H., Poder, A., Ferguson, M., Enweonye, I., Heineman, T. C., Hervé, C., Rheault, P., Talli, J., Wauters, D., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.05.110 · Cited by 36
WHO‐5 and BDI‐II are acceptable screening instruments for depression in people with diabetes
Rauwerda, N. L., Tovote, K. A., Peeters, A. C. T. M., Sanderman, R., Emmelkamp, P. M. G., Schroevers, M. J., & Fleer, J. (2018) · Diabetic Medicine · doi:10.1111/dme.13779 · Cited by 36
Pérez-Belmonte, L. M., Osuna-Sánchez, J., Millán-Gómez, M., López-Carmona, M. D., Gómez-Doblas, J. J., Cobos-Palacios, L., Sanz-Cánovas, J., Barbancho, M. A., Lara, J. P., Jiménez-Navarro, M., et al. (2019) · Annals of Medicine · doi:10.1080/07853890.2019.1613672 · Cited by 36
Leisure-Time Running Reduces the Risk of Incident Type 2 Diabetes
Wang, Y., Lee, D.-C., Brellenthin, A. G., Eijsvogels, T. M. H., Sui, X., Church, T. S., Lavie, C. J., & Blair, S. N. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.04.035 · Cited by 36
Laesser, C. I., Cumming, P., Reber, E., Stanga, Z., Muka, T., & Bally, L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070935 · Cited by 36
Corazzari, C., Matteucci, M., Kołodziejczak, M., Kowalewski, M., Formenti, A. M., Giustina, A., Beghi, C., Barili, F., & Lorusso, R. (2022) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.05.035 · Cited by 36
Spence, J. D., Viscoli, C. M., Kernan, W. N., Young, L. H., Furie, K. L., DeFronzo, R. A., Abdul‐Ghani, M. A., Dandona, P., & Inzucchi, S. E. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14687 · Cited by 36
Self-citationWang, W., Yang, J., Yang, G., Gong, Y., Patel, S. D., Zhang, C., Izumoto, T., & Ning, G. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12284 · Cited by 35
Self-citation(2006) · PubMed · Cited by 35
Kostev, K., Dippel, F.-W., & Rathmann, W. (2014) · Primary Care Diabetes · doi:10.1016/j.pcd.2013.10.001 · Cited by 35
Intensive insulin therapy for septic patients: A meta-analysis of randomized controlled trials.
Song, F., Zhong, L.-J., Han, L., Xie, G.-H., Xiao, C., Zhao, B., Hu, Y.-Q., Wang, S.-Y., Qin, C.-J., Zhang, Y., et al. (2014) · BioMed Research International · doi:10.1155/2014/698265 · Cited by 35
Floyd, B. D., Block, J. M., Buckingham, B. B., Ly, T., Foster, N., Wright, R., Mueller, C. L., Hood, K. K., & Shah, A. C. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12373 · Cited by 35
Navodia, N., Wahoush, O., Tang, T., Yost, J., Ibrahim, S., & Sherifali, D. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.04.010 · Cited by 35
Chen, Y., Liu, P., Chen, X., Li, Y., Zhang, F., & Wang, Y. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.01.017 · Cited by 35
Tharmaraja, T., Stahl, D., Hopkins, C. W. P., Persaud, S. J., Jones, P. M., Ismail, K., & Moulton, C. D. (2019) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000707 · Cited by 35
Hypertension in patients with diabetes
Sowers, J. R., Williams, M., Epstein, M., & Bakris, G. L. (2000) · Postgraduate Medicine · doi:10.3810/pgm.2000.04.990 · Cited by 34
Van Der Meeren, O., Peterson, J. T., Dionne, M., Beasley, R., Ebeling, P. R., Ferguson, M., Nissen, M. D., Rheault, P., Simpson, R. W., De Ridder, M., et al. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1164362 · Cited by 34
Colon neoplasia in patients with type 2 diabetes on metformin: A meta-analysis
Rokkas, T., & Portincasa, P. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.05.027 · Cited by 34
Wroe, A. L., Rennie, E. W., Sollesse, S., Chapman, J., & Hassy, A. (2018) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s1352465817000492 · Cited by 34
Nutrition education and body mass index in grades k-12: A systematic review
Price, C., Cohen, D., Pribis, P., & Cerami, J. (2017) · Journal of School Health · doi:10.1111/josh.12544 · Cited by 34
Li, M., Yang, Y., Jiang, D.-Q., Ying, M., Wang, Y., & Zhao, R. (2017) · Medicine · doi:10.1097/md.0000000000008161 · Cited by 34
Lu, J. B., Danko, K. J., Elfassy, M. D., Welch, V., Grimshaw, J. M., & Ivers, N. M. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-018826 · Cited by 34
McTavish, L., Corley, B., Weatherall, M., Wiltshire, E., & Krebs, J. D. (2018) · Diabetic Medicine · doi:10.1111/dme.13576 · Cited by 34
Harvie, M., Pegington, M., French, D., Cooper, G., McDiarmid, S., Howell, A., Donnelly, L., Ruane, H., Sellers, K., Foden, P., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6279-8 · Cited by 34
Mather, K. J., Bebu, I., Baker, C., Cohen, R. M., Crandall, J. P., DeSouza, C., Green, J. B., Kirkman, M. S., Krause-Steinrauf, H., Larkin, M., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108235 · Cited by 34
Self-citationBourry, J., Courteville, H., Ramdane, N., Drumez, É., Duhamel, A., Subtil, D., Deruelle, P., & Vambergue, A. (2020) · Diabetes Care · doi:10.2337/dc20-0904 · Cited by 34
van Raalte, D. H., Diamant, M., Ouwens, D. M., Ijzerman, R. G., Linssen, M. M. L., Guigas, B., Eringa, E. C., & Serné, E. H. (2013) · Diabetologia · doi:10.1007/s00125-013-3016-8 · Cited by 33
Type 2 diabetes in pregnancy: Rates of fetal malformations and level of preconception care
Callec, R., Perdriolle-Galet, E., Sery, G.-A., & Morel, O. (2014) · Journal of Obstetrics and Gynaecology · doi:10.3109/01443615.2014.925856 · Cited by 33
Schroeder, J. E., Liebergall, M., Raz, I., Egleston, R., Sussan, G. B., PEYSER, A. B., & Eldor, R. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1217 · Cited by 33
Aroda, V. R., Bailey, T. S., Cariou, B., Kumar, S., Leiter, L., Raskin, P., Zacho, J., Andersen, T. H., & Philis‐Tsimikas, A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12661 · Cited by 33
Robinson, E. M., Weaver, P. M., Chen, R., Streisand, R. M., & Holmes, C. S. (2016) · Health Psychology · doi:10.1037/hea0000406 · Cited by 33
Ell, K., Aranda, M. P., Wu, S., Oh, H., Lee, P.-J., & Guterman, J. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.07.001 · Cited by 33
Davidson, P., Ross, T., & Castor, C. (2018) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2018.03.007 · Cited by 33
Taskinen, M., Prato, S. D., Bujas‐Bobanovic, M., Louie, M. J., Letierce, A., Thompson, D. E., & Colhoun, H. M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.017 · Cited by 33
Guardado‐Mendoza, R., Salazar-López, S. S., Alvarez-Canales, M. F. D. L. L., Farfán-Vázquez, D., Martínez-López, Y. E., Jiménez-Ceja, L. M., Suárez-Pérez, E. L., Angulo-Romero, F., Evia-Viscarra, M. L., de Oca-Loyola, M. L. M., et al. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154054 · Cited by 33
AlHaidar, A. M., Alshehri, N., & Alhussaini, M. A. (2020) · Journal of Diabetes Research · doi:10.1155/2020/5151604 · Cited by 33
Autonomous artificial intelligence in diabetic retinopathy: From algorithm to clinical application
Channa, R., Wolf, R., & Abramoff, M. D. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296820909900 · Cited by 33
Asadi-Lari, M., Khosravi, A., Nedjat, S., Mansournia, M. A., Majdzadeh, R., Mohammad, K., Vaez-Mahdavi, M. R., Faghihzadeh, S., Haeri Mehrizi, A. A., & Cheraghian, B. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0384-6 · Cited by 32
Hu, R., Li, Y., Lv, Q., Wu, T., & Tong, N. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.05.504 · Cited by 32
Does belatacept improve outcomes for kidney transplant recipients? A systematic review
Talawila, N., & Pengel, L. H. M. (2015) · Transplant International · doi:10.1111/tri.12605 · Cited by 32
Seo, Y. B., Baek, J. H., Lee, J., Song, J. Y., Lee, J. S., Cheong, H. J., & Kim, W. J. (2015) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00288-15 · Cited by 32
Sohn, M., Epstein, N. U., Huang, E. S., Huo, Z., Emanuele, N., Stukenborg, G., Guihan, M., Li, J., & Budiman‐Mak, E. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.09.003 · Cited by 32
Carlson, J. N., Schunder-Tatzber, S., Neilson, C. J., & Hood, N. (2017) · Emergency Medicine Journal · doi:10.1136/emermed-2015-205637 · Cited by 32
Egede, L. E., Williams, J. S., Voronca, D., Gebregziabher, M., & Lynch, C. P. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-017-4023-0 · Cited by 32
Du, L., Wang, M., Kang, Y., Li, B., Guo, M., Cheng, Z., & Bi, C. (2017) · Oncotarget · doi:10.18632/oncotarget.14688 · Cited by 32
Kaneko, S., Ueda, Y., & Tahara, Y. (2018) · European Surgical Research · doi:10.1159/000494768 · Cited by 32
Yamaoka, K., Nemoto, A., & Tango, T. (2019) · Nutrients · doi:10.3390/nu11061373 · Cited by 32
de Ritter, R., Sep, S. J. S., van der Kallen, C. J. H., Schram, M. T., Koster, A., Kroon, A. A., van Greevenbroek, M. M. J., Eussen, S. J. P. M., Dagnelie, P. C., de Jong, M., et al. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000787 · Cited by 32
Beckmann, S., Drent, G., Ruppar, T. M., Nikolić, N., & Geest, S. D. (2019) · Transplantation · doi:10.1097/tp.0000000000002811 · Cited by 32
Predictive value of abnormal ankle-brachial index in patients with diabetes: A meta-analysis
Nie, F., He, J., Cao, H., & Hu, X. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108723 · Cited by 32
Functional hypogonadism among patients with obesity, diabetes, and metabolic syndrome
Louters, M., Pearlman, M., Solsrud, E., & Pearlman, A. (2022) · International Journal of Impotence Research · doi:10.1038/s41443-021-00496-7 · Cited by 32
Rosenlund, S., Hansen, T. W., Andersen, S., & Rossing, P. (2015) · Diabetic Medicine · doi:10.1111/dme.12950 · Cited by 31
Lee, J., Ryu, S., & Sung, K. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318774419 · Cited by 31
Shomali, M. E., Herr, D. L., Hill, P. C., Pehlivanova, M., Sharretts, J. M., & Magee, M. F. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0124 · Cited by 31
Primary prevention of diabetic retinopathy with fibrates: A retrospective, matched cohort study
Morgan, C. L., Owens, D. R., Aubonnet, P., Carr, E. S. M., Jenkins-Jones, S., Poole, C. D., & Currie, C. J. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-004025 · Cited by 31
Hospitalization costs and clinical outcomes in CABG patients treated with intensive insulin therapy
Cardona, S., Pasquel, F. J., Fayfman, M., Peng, L., Jacobs, S., Vellanki, P., Weaver, J., Halkos, M. E., Guyton, R. A., Thourani, V. H., et al. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.01.003 · Cited by 31
Self-citationOfori-Anyinam, O., Leroux-Roels, G., Drame, M., Aerssens, A., Maes, C., Amanullah, A., Schuind, A., Li, P., Jain, V. K., & Innis, B. L. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.09.012 · Cited by 31
for the Target Study Group, Crowther, C. A., Alsweiler, J. M., Hughes, R., & Brown, J. (2018) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-018-2060-2 · Cited by 31
Davis, T. M. E., Dwyer, P., England, M., Fegan, P. G., & Davis, W. A. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0331 · Cited by 31
Sterner Isaksson, S., Bensow Bacos, M., Eliasson, B., Thors Adolfsson, E., Rawshani, A., Lindblad, U., Jendle, J., Berglund, A., Lind, M., & Axelsen, M. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001971 · Cited by 31
An update on the Mediterranean, vegetarian, and DASH eating patterns in people with type 2 diabetes
Benson, G., & Hayes, J. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0073 · Cited by 30
Horwitz, D., Saunders, J. K., Ude-Welcome, A., Marie Schmidt, A., Dunn, V., Leon Pachter, H., & Parikh, M. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.01.016 · Cited by 30
Shechter, A., Foster, G. D., Lang, W., Reboussin, D. M., St‐Onge, M., Zammit, G., Newman, A. B., Millman, R. P., Wadden, T. A., Jakicic, J. M., et al. (2017) · Journal of Sleep Research · doi:10.1111/jsr.12559 · Cited by 30
Impact of dextrose dose on hypoglycemia development following treatment of hyperkalemia
Farina, N., & Anderson, C. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098618768725 · Cited by 30
The effect of bariatric surgery on peripheral polyneuropathy: A systematic review and meta-analysis
Aghili, R., Malek, M., Tanha, K., & Mottaghi, A. (2019) · Obesity Surgery · doi:10.1007/s11695-019-04004-1 · Cited by 30
Seaquist, E. R., Blonde, L., McGill, J. B., Heller, S. R., Kendall, D. M., Bumpass, J. B., Pompilio, F. M., & Grant, M. L. (2020) · Diabetic Medicine · doi:10.1111/dme.14202 · Cited by 30
Self-citationAutoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: A systematic review
Zhao, Z., Wang, X., Bao, X.-Q., Ning, J., Shang, M., & Zhang, D. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02699-1 · Cited by 30
Khan, K. S., Christensen, D. H., Nicolaisen, S. K., Gylfadottir, S. S., Jensen, T. S., Nielsen, J. S., Thomsen, R. W., & Andersen, H. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13542 · Cited by 30
Pichardo-Lowden, A., Umpierrez, G., Lehman, E. B., Bolton, M. D., DeFlitch, C. J., Chinchilli, V. M., & Haidet, P. M. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001557 · Cited by 30
Self-citationAbdelhaleem, I. A., Brakat, A. M., Adayel, H. M., Asla, M. M., Rizk, M. A., & Aboalfetoh, A. Y. (2021) · Medicina Clínica · doi:10.1016/j.medcli.2021.06.028 · Cited by 30
Lo, C., Toyama, T., Oshima, M., Jun, M., Chin, K. L., Hawley, C. M., & Zoungas, S. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009966.pub3 · Cited by 30
Oberholzer, J., Thielke, J., Hatipoglu, B., Testa, G., Sankary, H. N., & Benedetti, E. (2005) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.12.085 · Cited by 29
Hou, Y.-C., Hu, Q., Huang, J., Fang, J.-Y., & Xiong, H. (2017) · Oncotarget · doi:10.18632/oncotarget.13633 · Cited by 29
Change in sedentary time, physical activity, bodyweight, and HbA1c in high-risk adults
MCCARTHY, M., EDWARDSON, C. L., DAVIES, M. J., HENSON, J., GRAY, L., KHUNTI, K., & YATES, T. (2017) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001218 · Cited by 29
Impact of lifestyle behavior change on glycemic control in youth with type 2 diabetes
Kriska, A. M., ghormli, L. K. E., Copeland, K. C., HIGGINS, J. A., Ievers‐Landis, C. E., Katz, L. E. L., Trief, P. M., Wauters, A. D., Yasuda, P. M., Delahanty, L. M., et al. (2017) · Pediatric Diabetes · doi:10.1111/pedi.12526 · Cited by 29
Piatt, G. A., Rodgers, E. A., Xue, L., & Zgibor, J. C. (2018) · The Diabetes Educator · doi:10.1177/0145721718777855 · Cited by 29
Yaron, M., Sher, B., Sorek, D., Shomer, M., Levek, N., Schiller, T., Gaspar, M., Frumkin Ben-David, R., Mazor-Aronovitch, K., Tish, E., et al. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01300-1 · Cited by 29
Lerchbaum, E., Trummer, C., Theiler-Schwetz, V., Kollmann, M., Wölfler, M., Pilz, S., & Obermayer-Pietsch, B. (2019) · Nutrients · doi:10.3390/nu11081894 · Cited by 29
Márquez-Pardo, R., Torres-Barea, I., Córdoba-Doña, J.-A., Cruzado-Begines, C., García-García-Doncel, L., Aguilar-Diosdado, M., & Baena-Nieto, M.-G. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0319 · Cited by 29
Silverberg, E. L., Sterling, T. W., Williams, T. H., Castro, G., Rodriguez de la Vega, P., & Barengo, N. C. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18020792 · Cited by 29
High-risk population in sporadic pancreatic adenocarcinoma: guidelines for screening
Bruenderman, E. H., & Martin, R. C. G. (2014) · Journal of Surgical Research · doi:10.1016/j.jss.2014.06.046 · Cited by 28
Minder, A. E., Albrecht, D., Schäfer, J., & Zulewski, H. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.12.024 · Cited by 28
Fritsche, A., Stumvoll, M., Häring, H. U., & Gerich, J. E. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.2.6353 · Cited by 28
Bell, D. S. H., Dharmalingam, M., Kumar, S., & Sawakhande, R. B. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01408.x · Cited by 28
Le, N., Tomassini, J. E., Tershakovec, A. M., Neff, D., & Wilson, P. W. F. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001675 · Cited by 28
Giráldez‐García, C., Sangrós, F. J., Díaz-Redondo, A., Franch‐Nadal, J., Serrano, R., Díez, J., Buil‐Cosiales, P., Soidán, F. J. G., Artola, S., Ezkurra, P., et al. (2015) · Medicine · doi:10.1097/md.0000000000001935 · Cited by 28
Vellanki, P., Smiley, D. D., Stefanovski, D., Anzola, I., Duan, W., Hudson, M., Peng, L., Pasquel, F. J., & Umpierrez, G. E. (2016) · Diabetes Care · doi:10.2337/dc16-0406 · Cited by 28
Self-citationGuzman, C. B., Dulude, H., Piché, C., Rufiange, M., Sadoune, A. A., Rampakakis, E., Carballo, D., Triest, M., Zhang, M. X., Zhang, S., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13134 · Cited by 28
Murtola, T. J., Vihervuori, V. J., Lahtela, J., Talala, K., Taari, K., Tammela, T. L., & Auvinen, A. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0055-4 · Cited by 28
Research works printed but not linked: 9
- Gillett, 2009, International Expert Committee Report on the role of the A1C assay in the diagnosis of diabetes: Diabetes care, Clin Biochem Rev, 30, 197
- 1991, VIII. Study design, progress and performance, Diabetologia, 34, 877
- Nußbaumer, 2016, Ezetimibe-statin combination therapy, Dtsch arztebl int, 113, 445
- Whelton, 2018, Hypertens (Dallas. TX, 71, e13
- 2012, KDIGO clinical practice guideline for anemia in chronic kidney disease, Kidney Int Suppl, 2, 279
- Miller, 2015, Erratum. J Fam Pract, 64, 452
- Mechanick, 2019, Endocr Pract, 25, 1346
- 2019, Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study, Diabetes Care, 42, 601, 10.2337/dc18-1970 · DOI · Paper page
- American Diabetes Association. Medical management of pregnancy complicated by diabetes fourth edition. Jovanovic L, ed. Alexandria, VA: American Diabetes Association, 2009.
Cited by
Sorted by citations
Samson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
Self-citationDisorders of lipid metabolism. Clinical Guidelines 2023
Владиславович, Е. М., Kukharchuk, V. V., Сергиенко, И. В., Alieva, A. S., Antsiferov, M. B., Ansheles, A. A., Arabidze, G. G., Dm, A., Arutyunov, G. P., Ахмеджанов, Н. М., et al. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5471 · Cited by 270
Baricitinib and β-cell function in patients with new-onset type 1 diabetes
Waibel, M., Wentworth, J. M., So, M., Couper, J. J., Cameron, F. J., MacIsaac, R. J., Atlas, G., Gorelik, A., Litwak, S., Sanz-Villanueva, L., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306691 · Cited by 194
Honarmand, K., Sirimaturos, M., Hirshberg, E. L., Bircher, N. G., Agus, M. S. D., Carpenter, D. L., Downs, C. R., Farrington, E. A., Freire, A. X., Grow, A., et al. (2024) · Critical Care Medicine · doi:10.1097/ccm.0000000000006174 · Cited by 177
Self-citationNadolsky, K., Garvey, W. T., Agarwal, M., Bonnecaze, A., Burguera, B., Chaplin, M. D., Griebeler, M. L., Harris, S. R., Schellinger, J. N., Simonetti, J., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.07.017 · Cited by 141
Self-citation
Metadata
- Authors
- Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., Gardner, T. W., Garg, R., Garvey, W. T., Hirsch, I. B., Hurley, D. L., Izuora, K., Kosiborod, M., Olson, D., Patel, S. B., Pop-Busui, R., Sadhu, A. R., Samson, S. L., Stec, C., Tamborlane, W. V., Tuttle, K. R., Twining, C., Vella, A., Vellanki, P., & Weber, S. L.
- Affiliations
- Ochsner Health System (US)
- Emory University (US)
- Central Michigan University (US)
- Washington University in St. Louis (US)
- University at Buffalo, State University of New York (US)
- Cedars-Sinai Medical Center (US)
- The University of Texas at San Antonio (US)
- Scripps Whittier Diabetes Institute (US)
- University of Michigan (US)
- University of California, Los Angeles (US)
- University of Alabama at Birmingham (US)
- University of Washington (US)
- Mayo Clinic (US)
- University of Nevada, Las Vegas (US)
- Saint Luke's Hospital (US)
- Colorado Health Foundation (US)
- University of Cincinnati Medical Center (US)
- Houston Methodist (US)
- Mayo Clinic in Florida (US)
- American Association of Clinical Endocrinologists (US)
- Yale University (US)
- Maine Medical Center (US)
- Prisma Health (US)
- ORCID
- Blonde, Lawrence
- Umpierrez, Guillermo E.
- McGill, Janet B.
- Berga, Sarah L.
- Bush, Michael
- Chandrasekaran, Suchitra
- DeFronzo, Ralph A.
- Einhorn, Daniel
- Galindo, Rodolfo J.
- Gardner, Thomas W.
- Garg, Rajesh
- Garvey, W. Timothy
- Hirsch, Irl B.
- Hurley, Daniel L.
- Izuora, Kenneth
- Kosiborod, Mikhail
- Patel, Shailendra B.
- Sadhu, Archana R.
- Samson, Susan L.
- Tamborlane, William V.
- Tuttle, Katherine R.
- Vella, Adrian
- Vellanki, Priyathama
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2022-10
- Volume
- 28
- Issue
- 10
- Pages
- 923-1049
- ISSN
- 1530-891X (ISSN-L)
- PMC
- PMC10200071
- OpenAlex
- W4291397630
- Cited by
- 507
- References
- 1,959
- Citations by year
- 2026: 95 · 2025: 119 · 2024: 150 · 2023: 134 · 2022: 9
- FWCI
- 76.49
- Type
- journal article
- Language
- en
- Update notices
- erratum (2023-01-01)
- Open access
- bronze
- doi.org
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (K23DK123384, P30DK111024)
- National Institute of Diabetes and Digestive and Kidney Diseases
- BP
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- diabetes mellitus, comprehensive diabetes care, glycemic targets, blood glucose monitoring, diabetes complications, obesity, bariatric surgery, hypertension, dyslipidemia, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, cardiovascular disease, prediabetes, type 2 diabetes, type 1 diabetes, insulin therapy, hypoglycemia, diabetes in pregnancy, diabetes education, infertility, dietary supplements, social determinants of health, virtual care, cancer risk, pediatric diabetes care, depression, sleep medicine, team-based care
- MeSH terms
- Child, Diabetes Mellitus, Type 2, Endocrinology, Female, Humans, Hypoglycemic Agents, Insulin, Pregnancy, United States, Dyslipidemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-25 (prompt extract-v1).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
